


Focused Panel

Designed specifically for your advanced NSCLC patients

Alterations associated with NSCLC which are currently well-established



Alterations associated with: a) an FDA approved drug for a different tumor type, b) inclusion or exclusion criteria for clinical trials and/or c) indicators for resistance to therapy.



- SNVs + Indels - Hotspot Regions
- △ Fusions + SNVs + Indels
- △ CNVs + SNVs + Indels
- △ CNVs only
- △ SNVs + Indels - Exon Coverage 70% for PTEN, 88-100% for TP53, STK11 and CDKN2A
- △ Fusions

Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer

Genomic driver event	Available targeted agents with activity against the genomic driver event in patients with metastatic NSCLC
EGFR mutations	afatinib (GILOTRIF®), dacomitinib (VIZIMPRO®), erlotinib + ramucirumab, erlotinib + bevacizumab, erlotinib (TARCEVA®), gefitinib (IRESSA®), osimertinib (TAGRISSO®)
ALK rearrangements	alectinib (ALCENSA®), brigatinib (ALUNBRIG®), ceritinib (ZYKADIA®), crizotinib (XALKORI®), lorlatinib (LOBRENA®)
BRAF V600E mutations	dabrafenib (TAFINLAR®) + trametinib (MEKINIST®), vemurafenib (ZELBORAF®)
ROS1 rearrangements	ceritinib (ZYKADIA®), crizotinib (XALKORI®), entrectinib (ROZLYTREK™)
NTRK rearrangements	entrectinib (ROZLYTREK™), larotrectinib (VITRAKVI®)
MET amplifications/mutations	capmatinib (TABRECTA™), crizotinib (XALKORI®)
RET rearrangements	cabozantinib (COMETRIQ®), selpercatinib (RETEVMO™), vandetanib (CAPRELSA®)
HER2 mutations	ado-trastuzumab emtansine (KADCYLA®)

Order now to guide your decisions for your advanced NSCLC Patients



USA Toll Free
866.776.5907

Direct outside USA
+41 (0)21 721 06 00



neogenomics.com



@NeoGenomics



client.services@neogenomics.com



NeoGenomics Laboratories